KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,755,760 | -29.6% | 902,000 | -11.2% | 0.00% | 0.0% |
| Q2 2023 | $40,818,983 | +1.2% | 1,015,903 | +7.6% | 0.00% | 0.0% |
| Q1 2023 | $40,315,531 | -56.6% | 944,159 | -51.2% | 0.00% | -33.3% |
| Q4 2022 | $92,979,974 | +164.8% | 1,936,276 | +107.4% | 0.00% | +50.0% |
| Q3 2022 | $35,119,000 | +28.3% | 933,512 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $27,374,000 | -26.4% | 990,752 | +44.9% | 0.00% | 0.0% |
| Q1 2022 | $37,177,000 | -3.0% | 683,647 | +4.4% | 0.00% | 0.0% |
| Q4 2021 | $38,324,000 | +43.0% | 654,992 | -3.3% | 0.00% | +100.0% |
| Q3 2021 | $26,793,000 | -7.1% | 677,268 | -0.3% | 0.00% | -50.0% |
| Q2 2021 | $28,836,000 | -35.3% | 678,978 | -6.2% | 0.00% | -33.3% |
| Q1 2021 | $44,551,000 | +48.2% | 723,823 | +69.9% | 0.00% | +50.0% |
| Q4 2020 | $30,056,000 | +685.4% | 426,091 | +329.4% | 0.00% | – |
| Q3 2020 | $3,827,000 | +20.0% | 99,226 | +16.7% | 0.00% | – |
| Q2 2020 | $3,189,000 | – | 85,011 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |